Cancer Management and Research最新文献

{"title":"Iron-Dependent Cell Death: Exploring Ferroptosis as a Unique Target in Triple-Negative Breast Cancer Management.","authors":"Li-Kuan Tan, Jiaxing Liu, Cheng-Zhi Ma, Shaolong Huang, Feng-Hui He, Yang Long, Zhi-Sheng Zheng, Jia-Liang Liang, Nan Xu, Guanghui Wang, Yu-Fei Liu","doi":"10.2147/CMAR.S503932","DOIUrl":"10.2147/CMAR.S503932","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is characterized by aggressive behavior, high metastatic potential, and frequent relapses, presenting significant treatment challenges. Ferroptosis, a unique form of programmed cell death marked by iron-dependent lipid peroxidation, has emerged as a crucial factor in cancer biology. Recent studies indicate that TNBC cells possess a distinct metabolic profile linked to iron and glutathione, which may render them more susceptible to ferroptosis than other breast cancer subtypes. Moreover, ferroptosis plays a role in the interactions between immune cells and tumor cells, suggesting its potential to modulate the tumor microenvironment and influence the immune response against TNBC.Evidence reveals that ferroptosis not only affects TNBC cell viability but also alters the tumor microenvironment by promoting the release of damage-associated molecular patterns (DAMPs), which can recruit immune cells to the tumor site. Specific ferroptosis-related genes and biomarkers, such as ACSL4 and GPX4, demonstrate altered expression patterns in TNBC tissues, offering promising avenues for diagnostic and prognostic applications. Furthermore, in preclinical models, the induction of ferroptosis has been shown to enhance the efficacy of existing therapies, indicating a synergistic effect that could be harnessed for therapeutic benefit. The compelling link between ferroptosis and TNBC underscores its potential as a novel therapeutic target. Future research should focus on developing strategies that exploit ferroptosis in conjunction with traditional therapies, including the identification of natural compounds and efficacious ferroptosis inducers for personalized treatment regimens. This review elucidates the multifaceted implications of ferroptosis in TNBC, providing valuable insights for improving both diagnosis and treatment of this formidable breast cancer subtype.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"625-637"},"PeriodicalIF":2.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Efficacy and Clinical Significance of Lymphocyte Subsets, Granzyme B and Perforin in the Peripheral Blood of Patients with Invasive Breast Cancer Following Neoadjuvant Chemotherapy.","authors":"Han Liu, Ruinian Zheng, Zhaowei Zhuang, Liwen Xue, Minggui Chen, Yuluo Wu, Yan Zeng","doi":"10.2147/CMAR.S502155","DOIUrl":"10.2147/CMAR.S502155","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer, a predominant contributor to cancer-related mortality worldwide, is increasingly managed through the application of neoadjuvant chemotherapy (NAC). Analyzing the dynamic changes in peripheral blood lymphocyte subsets, granzyme B and perforin are crucial for investigating their roles in tumorigenesis, development and treatment; this study aimed to use these analyses to diagnose malignant breast tumor, assess the anti-tumor immunity and predict chemotherapy efficacy in breast cancer patients.</p><p><strong>Patients and methods: </strong>To address this objective, a total of 582 peripheral blood samples were collected from healthy controls (n=47), benign breast disease patients (n=401) and breast cancer patients (n=134). Lymphocyte subsets, along with granzyme B and perforin expression, were assessed using flow cytometry. Changes before and after NAC were also monitored.</p><p><strong>Results: </strong>Breast cancer patients exhibited reduced proportions and absolute counts of CD3⁺ and CD8⁺ T cells, increased NK cell percentage and CD4⁺/CD8⁺ ratio, and higher levels of granzyme B and perforin in CD3⁺, CD8⁺ T cells and NK cells. Post-NAC, the percentages of CD3⁺, CD4⁺, CD8⁺ T cells and NK cells increased, along with a higher CD4⁺/CD8⁺ ratio, while B cell percentages decreased compared to pre-NAC. Furthermore, the effective group showed higher percentages of CD3⁺, CD8⁺ T cells and lower percentages of B cells than the ineffective group post-NAC. Incidentally, Granzyme B and perforin expression in CD3⁺ and CD8⁺ T cells was elevated following postoperative chemotherapy.</p><p><strong>Conclusion: </strong>These findings indicated that peripheral blood lymphocyte subsets, along with granzyme B and perforin levels, could serve as potential biomarkers for differentiating benign from malignant breast tumors, assessing anti-tumor immunity and predicting chemotherapy efficacy.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"589-602"},"PeriodicalIF":2.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life Status and Its Influencing Factors Among Lung Cancer Chemotherapy Patients in China: A Cross-Sectional Study.","authors":"Fan Xu, Xiaoli Zhong, Qiao Li, Xi Luo, Na Wang, Jing Wang, Shaoju Xie, Jiquan Zhang","doi":"10.2147/CMAR.S510811","DOIUrl":"10.2147/CMAR.S510811","url":null,"abstract":"<p><strong>Background: </strong>Improving the quality of life (QOL) of lung cancer patients undergoing chemotherapy is an indispensable part of cancer treatment, as it not only pertains to their physical health but also to their psychological and social well-being. Previous research has primarily focused on investigating health-related quality of life, while studies specifically addressing the QOL of lung cancer patients remain underrepresented and under researched.</p><p><strong>Purpose: </strong>The study aims to investigate the current status of QOL among lung cancer patients and identify the predictive factors associated with QOL.</p><p><strong>Patients and methods: </strong>From January 2024 to June 2024, lung cancer patients undergoing chemotherapy will be recruited from the outpatient clinics or wards of a tertiary A-level hospital in Deyang City as research subjects. They will be surveyed using the general information questionnaire, the Self-rating Depression Scale (SDS), the Multidimensional Scale of Perceived Social Support (MSPSS), and the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale. Multiple linear regression analysis will be employed to determine the variables associated with QOL.</p><p><strong>Results: </strong>A total of 390 lung cancer patients undergoing chemotherapy were recruited for this study, with a male predominance accounting for 72.31%. The mean age was (59.11±11.37) years. The overall QOL score was (66.43±23.67). Age, family monthly income per capita, cancer clinical stage, depression, and perceived social support (PSS) were identified as independent factors influencing the QOL of lung cancer patients, accounting for 19.4% of the total variance.</p><p><strong>Conclusion: </strong>There is still considerable room for improvement in the overall QOL of lung cancer patients undergoing chemotherapy. Based on the analysis of influencing factors, targeted and personalized intervention measures should be implemented to enhance the QOL for these patients.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"603-615"},"PeriodicalIF":2.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retroperitoneal Myoepithelial Carcinoma: A Case Report and Literature Review.","authors":"Tong Wei, Hongmin Quan, Rengui Wang, Xiaoli Sun","doi":"10.2147/CMAR.S494121","DOIUrl":"10.2147/CMAR.S494121","url":null,"abstract":"<p><strong>Background: </strong>Myoepithelial carcinoma is rare, and myoepithelial carcinoma occurring outside the head and neck is even rarer. We reported one case of retroperitoneal myoepithelial carcinoma.</p><p><strong>Case summary: </strong>A 63-year-old woman who underwent computed tomography (CT) for progressive abdominal distension revealed a left retroperitoneal mass and subsequently underwent surgical treatment where the mass was completely removed with a postoperative diagnosis of retroperitoneal myoepithelial carcinoma. A follow-up CT review 40 days after surgery revealed a recurrence of the mass. After 8 months of chemotherapy and targeted immunotherapy, a follow-up review of the CT images revealed a gradual reduction in the mass. Four months after the cessation of chemotherapy and targeted drug combined immunotherapy, a follow-up review via CT revealed another recurrence and enlargement of the mass.</p><p><strong>Conclusion: </strong>CT of retroperitoneal myoepithelial carcinoma revealed a massive cystic solid mass in the abdominal cavity and retroperitoneum. The solid region of the mass was significantly enhanced and the cystic region was without enhancement on enhanced CT; the mass involved the adjacent duodenum, partial jejunum, and left renal vein. PET‒CT imaging revealed hypermetabolism in the solid region of the mass and no hypermetabolism in the cystic region.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"617-624"},"PeriodicalIF":2.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Levels of MUC and JADE1 Predict Poor Prognosis of Patients with Gastric Cancer.","authors":"Zhaowei Zhu, Yanming Hua, Jianta Wu, Jianfeng Mei","doi":"10.2147/CMAR.S493015","DOIUrl":"10.2147/CMAR.S493015","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the relationship between the expression of mucin (MUC) and JADE family PHD finger factor 1 (JADE1) and <i>Helicobacter pylori</i> (HP) infection as well as depth of tumor invasion in gastric cancer.</p><p><strong>Methods: </strong>According to the results of immunohistochemical staining, 132 gastric cancer patients diagnosed and treated in our hospital from March 2018 to May 2019 were divided into MUC2 negative group (n=43), MUC2 positive group (n=89), JADE1 negative group (n=36) and JADE1 positive group (n=96). The relationship between MUC2 and JADE1 expression and clinicopathological features of gastric cancer was analyzed. The diagnostic value of MUC2 and JADE1 alone or in combination in gastric cancer was analyzed using ROC curve.</p><p><strong>Results: </strong>The MUC2 and JADE1 expressions in gastric cancer tissues was increased (P<0.05). MUC2 and JADE1 expressions were related to different tumor size, differentiation degree, HP infection, lymph node metastasis, depth of tumor invasion and Lauren classification (P<0.05). Kaplan-Meier survival analysis showed that the survival rate of patients with negative expression of MUC2 and JADE1 was significantly lower than that of patients with positive expression of MUC2 and JADE1 (P<0.05). The area under the curve, sensitivity and specificity of MUC2 alone, JADE1 alone and the two combined in detection of gastric cancer was 0.774, 72.46% and 80.03%, 0.796, 82.14% and 76.48%, and 0.918, 91.34% and 89.57%, respectively.</p><p><strong>Conclusion: </strong>The expressions of MUC2 and JADE1 in gastric cancer tissues were significantly increased, and their expressions were associated with tumor size, differentiation degree, HP infection, lymph node metastasis, depth of tumor infiltration, Lauren's staging. The combined detection of the two has a high value in the diagnosis of gastric cancer. Analysis of the relationship between MUC2 and JADE1 expression and HP infection is helpful for clinical medical staff to effectively evaluate the condition of patients.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"577-587"},"PeriodicalIF":2.5,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Ferroptosis-Immunity-Related Signature Genes in Cervical Cancer Radiotherapy Resistance and Risk Modeling.","authors":"Xianzhen Zhang, Aihua Li, Wanqi Zhu, Qiufen Guo, Qian Wu, Hong Zhao, Yunbei Yu, Peng Xie, Xiaolin Li","doi":"10.2147/CMAR.S501663","DOIUrl":"https://doi.org/10.2147/CMAR.S501663","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to clarify the genome of ferroptosis in the genes involved in radiotherapy resistance and regulation of tumor immune microenvironment by multigene analysis of cervical cancer (CC) patients.</p><p><strong>Methods: </strong>Different radiation sensitivity samples from CC patients were collected for RNA sequencing. Differentially expressed genes (DEGs) between the RNA dataset and the GSE9750 dataset were considered as radiotherapy-DEGs. The intersection genes of radiotherapy-DEGs with ferroptosis-related genes (FRGs) and the intersection genes of radiotherapy-DEGs with immune-related genes (IRGs) were labeled as FRGs-IRGs-DEGs (FIGs). A risk model was established by prognostic genes selected from FIGs by univariate Cox analysis and least absolute shrinkage and selection operator (LASSO) analysis. The results were further validated using samples from CC tissue samples.</p><p><strong>Results: </strong>The 329 DEGs related to CC radiotherapy were identified. LSAAO analysis was utilized to identify five prognostic genes (<i>CALCRL, UCHL1, GNRH1, ACVRL1</i>, and <i>MUC1</i>) from six candidate prognosis genes and construct a risk model. The risk model demonstrated favorable effectiveness in predicting outcomes at 1, 3, and 5 years, as evidenced by ROC curves. Univariate and multivariate Cox regression analysis demonstrated that <i>CALCRL, GNRH1</i>, and <i>MUC1</i> were independent prognostic factors. The results of functional similarity analysis showed that <i>CALCRL, UCHL1, ACVRL1</i> and <i>MUC1</i> had high average functional similarity. The results of PCR and IHC showed the same trend with the results above.</p><p><strong>Discussion: </strong>A novel prognostic model related to ferroptosis and immune microenvironment in CC radiotherapy was developed and validated, providing valuable guidance for personalized anti-cancer therapy.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"557-575"},"PeriodicalIF":2.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibitory Effects of Paclitaxel-Loaded Iron Oxide Nanoparticles on Non-Small Cell Lung Cancer by Enhancing Autophagy-Dependent Ferroptosis and Apoptosis Pathways.","authors":"Rongchu Deng, Guanghong Liang, Wenqing Chen, Qi Nie, Jian Wen","doi":"10.2147/CMAR.S497238","DOIUrl":"10.2147/CMAR.S497238","url":null,"abstract":"<p><strong>Background: </strong>Iron oxide nanoparticles coated with paclitaxel (IONP@PTX) are frequently applied to various tumor types. However, inhibitory effect and possible mechanism of IONP@ PTX on non-small-cell lung cancer (NSCLC) remain unclear.</p><p><strong>Objective: </strong>This work aimed to assess inhibitory effects and potential mechanisms of IONP@PTX on lung cancer A549 cells and further explore the nanomedicine delivery systems for applications in cancer therapies.</p><p><strong>Methods: </strong>Morphology features and qualities of IONP@PTX were directly assessed. After treatment of A549 cells with either PTX or IONP@PTX, cell viability and apoptosis were separately detected by CCK‑8 assay and flow cytometry. In addition, intracellular iron ion, lipid peroxidation (LPD) and reactive oxygen species (ROS) were identified by using an iron colorimetric assay kit, DCFH-DA and C11-BODIPY fluorescent probe, respectively. Moreover, the expression levels of autophagy-, ferroptosis-, and apoptosis-related proteins were measured by Western blot.</p><p><strong>Results: </strong>The synthesized IONP@PTX had a core particle size of about 10 nm and a hydrated particle size of 31.01±2.47 nm. In comparison with PTX, IONP@PTX had a stronger anti-tumor effect on A549 cells, with considerably higher levels of ROS, LPD, and total iron ion concentration (<i>P</i><0.05). Likewise, IONP@PTX markedly reduced the expression levels of GPX4, FTH, and SLC7A11 proteins whereas obviously increased the expression levels of LC3II/I and ACSL4 proteins (<i>P</i><0.05). Furthermore, the inhibitory effects of both PTX and IONP@PTX on A549 cells could be evidently reversed by additional 3-methyladenine (3-MA) or ferrostatin-1. Interestingly, the apoptosis rates of A549 cells, together with the expression level of pro-apoptotic protein Cleaved caspase-3, were significantly higher in the IONP@PTX group than those in the control and PTX groups (<i>P</i><0.05).</p><p><strong>Conclusion: </strong>IONP@PTX inhibits the proliferation of human lung cancer A549 cells by enhancing autophagy-dependent ferroptosis and apoptosis pathways.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"541-555"},"PeriodicalIF":2.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Value of Serum sTim-3, CEA, CA15-3 for Postoperative Recurrence of Breast Cancer.","authors":"Ting Shen, Hongming Fang, Jialong Wu, Yuan Qin, Xiumei Zhou, Xueqin Zhao, Biao Huang, Haiyan Gao","doi":"10.2147/CMAR.S508321","DOIUrl":"10.2147/CMAR.S508321","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical value of serum soluble T cell immunoglobulin 3 (sTim-3) on postoperative recurrence of breast cancer (BC).</p><p><strong>Methods: </strong>A highly sensitive time-resolved fluorescence immunoassay (TRFIA) was employed to measure sTim-3. Quantification of serum sTim-3 in 172 BC patients more than one-year postoperative (96 patients with stage I + II, 76 patients with stage III + IV; 31 patients with postoperative recurrence, and 141 patients with postoperative non-recurrence) and 51 healthy controls (HC). To evaluate the difference of serum sTim-3 in different stages of BC and its clinical value for postoperative recurrence of BC.</p><p><strong>Results: </strong>The serum sTim-3 level of BC patients with stage III + IV (21.62 (17.27, 29.78)) were significantly higher than HC (4.49 (3.30, 7.60)), patients with stage I + II (14.96 + 4.94) (P < 0.0001). Serum sTim-3 level of BC patients with postoperative recurrence (21.8(12.40,34.20) were significantly higher than those without recurrence (17.13 ± 6.44) (P = 0.0130). When the serum sTim-3 level was below 11.8 ng/mL, the negative predictive values of sTim-3, CEA and CA15-3 were 90.9%, 68.0% and 67.1%, respectively, and the negative likelihood ratios were 0.16, 0.77 and 0.81, respectively. The positive rate of combined detection of sTim-3, CEA and CA15-3 was 58.1%, higher than single detection of CEA (22.6%) and CA15-3 (19.4%).</p><p><strong>Conclusion: </strong>Serum sTim-3 levels may assist in the staging of BC. Combined detection of sTim-3, CEA, and CA15-3 can be used to routinely monitor the progression of BC and indicate the risk of postoperative BC recurrence.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"517-526"},"PeriodicalIF":2.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative and Postoperative Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Measured From the Peripheral Blood of Patients with Colorectal Cancer.","authors":"Hua-Jun Lu, Guo-Chao Ren, Yan Wang, Chao-Qun Wang, Da-Hai Zhang","doi":"10.2147/CMAR.S504532","DOIUrl":"https://doi.org/10.2147/CMAR.S504532","url":null,"abstract":"<p><strong>Background: </strong>The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been confirmed to be related to the clinicopathological features and prognosis of colorectal cancer (CRC) patients. However, the results have been inconsistent, and few studies have focused on a specific point in time during surgery and dynamic changes prior to and after surgery.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 349 CRC patients and explored the value of NLR, PLR and their dynamic changes in predicting clinicopathological variables and prognosis in CRC.</p><p><strong>Results: </strong>Preoperative NLR (Pre-NLR) was correlated with CEA, CA199 levels, tumor location and tumor stage (<i>P</i>=0.041, <i>P</i>=0.002, <i>P</i>=0.001 and <i>P</i>=0.012, respectively), whereas postoperative NLR (post-NLR) was relevant to age, sex, CA125 levels and T stage significantly (<i>P</i>=0.032, <i>P</i>=0.002, P=0.026, P=0.019, respectively). When comparing post- and pre-NLR values, there was a positive connection between increases in NLR and BMI, tumor location, T stage, and tumor stage (<i>P</i>=0.034, <i>P</i>=0.005, <i>P</i>=0.023, <i>P</i>=0.023, respectively). In addition, Preoperative PLR (pre-PLR) was correlated with sex, smoke and drink history, CEA and CA199 levels, tumor location, T stage and tumor stage (<i>P</i>=0.006, <i>P</i>=0.037, <i>P</i>=0.040, <i>P</i>=0.006, <i>P</i>=0.005, <i>P</i><0.001, <i>P</i>=0.007, <i>P</i>=0.003 respectively), while postoperativePLR (post-PLR) was only associated with tumor location (<i>P</i>=0.010). Increases in PLR were significantly related to sex, smoking history, tumor location and differentiation (<i>P</i>=0.001, <i>P</i>=0.002, <i>P</i><0.001, <i>P</i>=0.034, respectively). Patients with CRC who had a high post-PLR experienced significantly shorter relapse-free survival (RFS) compared to other patients (HR 0.607 (0.381-0.968), <i>P</i>=0.036). Furthermore, this high post-PLR has tendency association with shorter overall survival (OS) (HR 0.596 (0.338-1.050), <i>P</i>=0.076).</p><p><strong>Conclusion: </strong>These findings suggest that levels and changes in NLR/PLR are associated with several unfavorable clinicopathological features in CRC patients. Furthermore, patients with high levels of post-PLR exhibit a worse prognosis.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"527-540"},"PeriodicalIF":2.5,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Successful Nodular Basal Cell Carcinoma Defect Closure On The Mid-Cheek Using Modified Mini Cheek Advancement Flap.","authors":"Muhamad Radyn Haryadi Widjaya, Teja Koswara","doi":"10.2147/CMAR.S513161","DOIUrl":"10.2147/CMAR.S513161","url":null,"abstract":"<p><p>Basal cell carcinoma (BCC) is the most common type of malignant skin tumour. This skin cancer is further divided into pigmented, morpheaform, superficial, and nodular BCC (nBCC), as well as fibroepithelioma of Pinkus. Despite its slow growth and very rare metastases, BCC might cause morbidity due to its tendency to relapse as well as its locally invasive nature, especially when located on the face. Wide local excision might be an effective treatment option for BCC and is usually followed by a surgical defect reconstruction procedure. We report a case of 61-year-old woman who presented with a superficially ulcerated, well-defined, hyperpigmented nodule with a rolled edge and frequent episodes of bleeding, as well as suppuration on the right mid-cheek in the past year before the consultation. The lesion was excised and the sample was sent for histopathological examination, revealing tumour mass in a palisading arrangement at the edges, forming solid islands, which is consistent with the diagnosis of nBCC with tumour-free edges. Defect closure with the mini cheek advancement flap (mini-CAF) technique yielded good results after eight months without any recurrence in one year. Skin flap techniques vary widely, among them is the cheek advancement flap technique which might be used for reconstructing defects on the mid-cheek. This flap technique can be modified as mini-CAF by placing a flap incision on the natural creases of the mid-cheek, namely the palpebromalar and nasojugal creases. Mini-CAF offer the advantage as its ability to camouflage the excision line by utilising the natural creases of the face, thus resulting in an aesthetically and functionally favourable result.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"499-507"},"PeriodicalIF":2.5,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}